Johnson & Johnson plans to separate orthopaedics unit DePuy Synthes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St slips as climbing oil, yields amplify inflation fears
- Oil jumps 5%, then pares gains after Trump says no attack on Iran this month
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- CoreWeave stock drops on dilution fears and debt concerns
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business
October 14, 2025 6:21 AM EDTStrengthens focus of Johnson & Johnson as an innovation powerhouse and accelerates the portfolio shift of its MedTech Segment to higher-growth and higher-margin markets
Standalone orthopaedics business would operate as DePuy Synthes and be the largest, most comprehensive orthopaedics-focused company in the world
Namal Nawana appointed to serve as Worldwide President of DePuy Synthes
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (the Company) (NYSE: JNJ) today announced the Companys intent to separate its Orthopaedics business to enhance... More



